View Older Stories View More Recent Stories

Jan 17, 2023 12:24PM Forsee Power Announces the Appointment of Jean-Yves Quentel as Group CFO
Jan 13, 2023 04:51PM Form 4 Kymera Therapeutics, For: Jan 11 Filed by: Atlas Venture Associates Opportunity I, L.P.
Jan 12, 2023 10:00AM Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity
Jan 6, 2023 01:03PM Biotech Industry Leaders Join Deep Genomics Board of Directors and Scientific Advisory Board
Jan 3, 2023 09:29PM Form 4 Disc Medicine, Inc. For: Dec 29 Filed by: Atlas Venture Fund X, L.P.
Jan 3, 2023 09:22PM Form 3 Disc Medicine, Inc. For: Dec 29 Filed by: Atlas Venture Opportunity Fund II, L.P.
Dec 29, 2022 05:15PM Disc Medicine Announces Completion of Merger with Gemini Therapeutics
Dec 19, 2022 08:30AM CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
Dec 16, 2022 05:04PM Form 4 Kymera Therapeutics, For: Dec 14 Filed by: Atlas Venture Associates Opportunity I, L.P.
Dec 15, 2022 04:06PM Form SC 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
Dec 14, 2022 04:55PM Form 4 Dyne Therapeutics, Inc. For: Dec 12 Filed by: Atlas Venture Opportunity Fund II, L.P.
Dec 14, 2022 04:54PM Form 4 Day One Biopharmaceutica For: Dec 12 Filed by: Atlas Venture Fund XI, L.P.
Dec 12, 2022 07:00AM Rectify Pharmaceutical Announces Publication of Trends in Molecular Medicine Review Article Highlighting the Therapeutic Potential of the ABC Transporter Superfamily
Dec 8, 2022 06:30AM Be Biopharma Appoints John Mayfield, Ph.D., as Chief Business Officer
Dec 6, 2022 05:01PM Form SC 13D/A Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Nov 10, 2022 06:56AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 10, 2022 06:55AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 10, 2022 06:53AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 10, 2022 06:53AM Form 13F-NT Atlas Venture Fund VIII, For: Sep 30
Nov 10, 2022 06:53AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 9, 2022 04:28PM Form 13F-HR Atlas Venture Life Scien For: Sep 30
Nov 4, 2022 04:32PM Form 4 Kymera Therapeutics, For: Nov 02 Filed by: Atlas Venture Associates Opportunity I, L.P.
Nov 3, 2022 04:15PM Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Nov 3, 2022 04:15PM Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Nov 2, 2022 07:00AM Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022
Nov 1, 2022 07:35PM Form 4 Kymera Therapeutics, For: Oct 28 Filed by: Atlas Venture Associates Opportunity I, L.P.
Oct 18, 2022 07:00AM Versanis Bio Appoints Kenneth Attie, M.D., and Aditya Venugopal, Ph.D., to Key Leadership Roles
Oct 14, 2022 06:30AM Matchpoint Therapeutics Launches with $100 Million to Deliver on the Promise of Precision Covalent Medicines for Immune Diseases
Oct 6, 2022 07:00AM Rectify Pharmaceuticals Appoints Robert Hughes as Executive Vice President, Drug Discovery and Preclinical Development, and Xiaobing Li as Chief Development Officer
Oct 5, 2022 06:00AM Valence Discovery Grows Leadership Team with Key Drug Discovery Hires
Sep 29, 2022 04:30PM Form SC 13D Third Harmonic Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.
Sep 28, 2022 03:01AM Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Sep 28, 2022 03:00AM Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors
Sep 21, 2022 04:59PM Form 4 Day One Biopharmaceutica For: Sep 19 Filed by: Atlas Venture Fund XI, L.P.
Sep 20, 2022 08:00AM Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition
Sep 20, 2022 07:33AM Generation Bio (GBIO) Appoints Phillip Samayoa as Chief Strategy Officer
Sep 20, 2022 07:30AM Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
Sep 20, 2022 07:30AM Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
Sep 19, 2022 04:52PM Form 4 Third Harmonic Bio, Inc. For: Sep 19 Filed by: Atlas Venture Associates XI, LLC
Sep 14, 2022 06:04PM Form 3 Third Harmonic Bio, Inc. For: Sep 14 Filed by: Atlas Venture Associates XI, LLC
Sep 14, 2022 05:06PM Form SC 13D/A Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Sep 12, 2022 07:00AM Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
Sep 8, 2022 06:00AM Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules for Precision Phosphorylation to Modulate and Repair Disease-Driving Proteins
Aug 23, 2022 07:00AM K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001
Aug 11, 2022 10:01AM ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Aug 11, 2022 08:00AM PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer
Aug 11, 2022 06:01AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 11, 2022 06:01AM Form 13F-HR Atlas Venture Associates For: Jun 30
Aug 11, 2022 06:01AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 11, 2022 06:01AM Form 13F-NT Atlas Venture Associates For: Jun 30
View More Recent Stories View Older Stories